Updates are available Correction dated 2025-03-03
Click to view Correction: https://doi.org/10.1038/s41584-025-01231-y
-
Authors
Abraham, David J. https://orcid.org/0000-0001-8952-6057
Black, Carol M.
Denton, Christopher P. https://orcid.org/0000-0003-3975-8938
Distler, Jörg H. W.
Domsic, Robyn https://orcid.org/0000-0002-2765-0922
Feghali-Bostwick, Carol https://orcid.org/0000-0002-6750-6407
Gourh, Pravitt
Hinchcliff, Monique https://orcid.org/0000-0002-8652-9890
Kolling, Fred IV
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Lafyatis, Robert https://orcid.org/0000-0002-9398-5034
Landegren, Ulf
Mahoney, J. Matthew
Martin, Javier
Matucci-Cerinic, Marco
McMahan, Zsuzsanna H.
Mora, Ana L.
Mouthon, Luc
Rabinovitch, Marlene
Rojas, Mauricio
Rubin, Kristofer
Trojanowska, Maria https://orcid.org/0000-0001-9550-7178
Varga, John
Whitfield, Michael L. https://orcid.org/0000-0002-0862-6003
Gabrielli, Armando https://orcid.org/0000-0003-3189-5516
Krieg, Thomas https://orcid.org/0000-0001-5616-8476
- License Information
-
More Information
Article History
Accepted: 20 December 2024
First Online: 14 February 2025
Change Date: 3 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41584-025-01231-y
Competing interests
: J.H.W.D. has consultancy relationships with AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche and UCB, and has received research funding from AbbVie, Anamar, Argenx, ARXX, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, ExoTherapeutics, Galapagos, GSK, Inventiva, Kiniksa, Lassen, Novartis, Sanofi-Aventis, RedX, UCB and Zenasbio. J.H.W.D. is CEO of 4D Science and Scientific Lead of FibroCure. R.D. has received funding from and is a consultant for Aisa Pharma Inc and AstraZeneca. M.K. has received funding from and is a consultant for Boehringer Ingelheim, Mochida, Kissei, GSK, AstraZeneca, Mitsubishi Tanabe, Janssen, Biogen, Novartis, Chugai and Asahi Kasei Pharma. U.L. is the founder of Olink Proteomics and has stocks in Navinci and SampleFacts.
